Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tallulah Holmstrom

Internal Medicine Lugoff, SC Medical Doctor

NPI 1053363887 CMS profile 138725

710 Dewitt Dr, Lugoff, SC 29078

Open in the dashboard

General payments

$2,888

173 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tallulah Holmstrom of Lugoff, SC is reported in the CMS Open Payments database as having received $2,888 across 173 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $102 1
2024 General $19 1
2022 General $13 1
2021 General $1,063 73
2020 General $876 48
2019 General $816 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tallulah Holmstrom
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Tallulah Holmstrom were reported at $102. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Tallulah Holmstrom Internal Medicine median Middle half National median
2019 $816 $159 $48–$570 $163
2020 $876 $119 $33–$402 $114
2021 $1,063 $135 $37–$521 $132
2022 $13 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $19 $154 $47–$537 $164
2025 $102 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $314 16 payments
  2. Novo Nordisk Inc $261 12 payments
  3. Amgen Inc. $242 16 payments
  4. Teva Pharmaceuticals USA, Inc. $239 10 payments
  5. AstraZeneca Pharmaceuticals LP $235 14 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $225 10 payments
  7. Janssen Pharmaceuticals, Inc $170 7 payments
  8. AbbVie, Inc. $162 15 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $137 9 payments
  10. Amarin Pharma Inc. $130 9 payments
  11. Other $772 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,772 170 payments
  2. Education $116 3 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $256 11 payments
  2. Ozempic $240 11 payments
  3. FARXIGA $196 11 payments
  4. JARDIANCE $195 8 payments
  5. XARELTO $153 5 payments
  6. AJOVY $149 9 payments
  7. Prolia $148 10 payments
  8. XIFAXAN $137 9 payments
  9. EVENITY $126 8 payments
  10. UBRELVY $118 10 payments
  11. Other $1,916 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 124 drugs

Part D claims

6,408

Median for Internal Medicine: 777

Drug cost

$394,600

Median for Internal Medicine: $73,373

Branded share of claims

15.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 45 $54,335
Eliquis Apixaban Brand 71 $51,206
Rybelsus Semaglutide Brand 28 $39,913
Mounjaro Tirzepatide Brand 28 $32,754
Jardiance Empagliflozin Brand 24 $27,052
Repatha Sureclick Evolocumab Brand 14 $20,099
Myrbetriq Mirabegron Brand 27 $19,192
Xarelto Rivaroxaban Brand 14 $11,510
Linzess Linaclotide Brand 16 $10,342
Aimovig Autoinjector Erenumab-Aooe Brand 11 $8,143

The 10 drugs with the highest cost, of 124 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$134,955

Of which drugs: $21,677

Medicare patients

531

Average age 76

Services billed

3,281

440 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 47%
Osteoporosis 28%
Diabetes 27%
Ischemic heart disease 27%
Atrial fibrillation 15%
Chronic kidney disease 15%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 37 37 $10,724
Vaccine for influenza for injection into muscle 90662 Office 70 70 $5,698

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xhance
  • OptiNose US, Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

173 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record